Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
Acute Promyelocytic Leukemia
DRUG: venetoclax
the rate of differential symdrom, DS, known as retinoic acid syndrome, is a severe complication of ATRA or ATO during the differentiation of promyelocytes. Signs of DS are presented as fever, weight gain, hypertension, dyspnoea, radiographic opacities, peripheral edema and acute renal failure., the induction regimen (21 days to 28 days)
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.